Counsyl→Myriad Genetics
Acquisition · Cash · MYGN · announced May 28, 2018
Announced
May 28, 2018
Closed
Aug 1, 2018
Economics
Cash()
Pre-deal · pre-deal mark: 2018, year precision · Myriad Genetics 8-K filing, SEC EDGAR — Counsyl acquisition
~$375M ($225M cash + $150M equity consideration)
Target
Counsyl
Diagnostics · Diagnostic / genomic
HQ South San Francisco, CA · Founded 2007
Prenatal and carrier genetic screening — Foresight carrier screen and Prequel NIPT (non-invasive prenatal testing); one of largest reproductive genetics labs in US
- Globe Newswire — Myriad Genetics press release (May 28, 2018)
- Myriad Genetics investor relations
Acquirer
Myriad Genetics (MYGN)
Diagnostics
HQ Salt Lake City, UT
Why this buyer
Curated copy from the verified dataset — not an 8-K LLM summary
Foresight carrier screen and Prequel NIPT add prenatal/reproductive genetics to Myriad's women's health portfolio — one of largest US reproductive genetics labs
Evidence ladder
Secondary (press / IR)
Globe Newswire — Myriad Genetics press release (May 28, 2018)
Primary (regulatory / filing)
SEC EDGAR 8-K https://www.sec.gov/Archives/edgar/data/899923/000119312518175904/d568140d8k.htm
Open source
Limitations
- ~$375M ($225M cash + $150M equity consideration)
- Pre-deal valuation sourced from: Myriad Genetics 8-K filing, SEC EDGAR — Counsyl acquisition. Pre-deal market-cap and funding citations do not corroborate the acquisition.
Valuation peers · Diagnostics
Same sector, same deal type, announced within ±3 years, disclosed value within 0.25×–4× of this transaction. Ranked by evidence class, then same acquirer.
| Target | Acquirer | Announced | Value | Why included |
|---|---|---|---|---|
| nVision Medical | Boston Scientific | Apr 16, 2018 | same evidence class | |
| EUROIMMUN | PerkinElmer (Revvity) | Jun 16, 2017 | same evidence class | |
| Sequenom | LabCorp | Jul 27, 2016 | same evidence class | |
| Igenomix | Vitrolife | Jul 8, 2021 | same evidence class |
Same-sector adjacency — not valuation peers
These deals share the sector tag and window but sit outside the 0.25×–4× value band. The dataset keeps them for clinical adjacency, not as price comps.
| Target | Acquirer | Announced | Value | Vs this deal |
|---|---|---|---|---|
| Alere | Abbott Laboratories | Feb 1, 2016 | ||
| Thrive Earlier Detection | Exact Sciences | Oct 27, 2020 |
Other verified deals by Myriad Genetics
Acquirer program history not already listed as a valuation peer or adjacency row.
| Target | Acquirer | Announced | Value | Sector |
|---|---|---|---|---|
| Gateway Genomics | Myriad Genetics | Nov 1, 2022 | Diagnostics | |
| Sividon Diagnostics | Myriad Genetics | May 31, 2016 | Breast Health |
Patient empowerment context
Empowerment context — Counsyl
Curated survey mappingHLTH/Outcomes4Me 2022 surveyed breast cancer patients (n=1,828). Breast cancer care continuum (HLTH 2022). Rows below are analyst-curated mappings to cited survey items — not live patient outcomes for this target.
- Not recommended genetic testing (NCCN: almost all should)37%cited HLTH 2022
Other curated mappings on these gaps: Biotheranostics, Endomagnetics, Genomic Health, Foundation Medicine
Full cited gap matrix →Related verified workspaces
Lacuna is a curated public-source sample, not a census of women's-health M&A. Coverage varies by sector, geography, disclosure availability, and women's-health scope. Undisclosed transaction values are excluded from disclosed-value totals.
Curated verified dataset v9 · updated 2026-09-20 · 2 citations on this deal · Data compiled from public sources for educational visualization. Verify independently before any commercial use.